Interpreting the interphase gap effect on the electrically evoked compound action potential

Yi Yuan,1 Jeffrey Skidmore,1 and Shuman He1,2,a)

1Department of Otolaryngology–Head and Neck Surgery, The Ohio State University, Columbus, Ohio 43212, USA
2Department of Audiology, Nationwide Children’s Hospital, Columbus, Ohio 43205, USA
yi.yuan@osumc.edu, Jeffrey.Skidmore@osumc.edu, Shuman.He@osumc.edu

Abstract: This study demonstrated the effects of using different quantification methods and parameter scales on the sensitivity of the electrically evoked compound action potential (eCAP) to changes in the interphase gap (IPG). The IPG effect measured in two groups of cochlear implant (CI) users with different cochlear nerve (CN) health on seven eCAP measures was quantified using an absolute and a proportional difference method. The IPG effect provides an indicator for the functional status of the CN in human CI users. Specifying how the IPG effect is quantified is critical for accurate result interpretation.

© 2022 Author(s). All article content, except where otherwise noted, is licensed under a Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
[Editor: Qian-Jie Fu] https://doi.org/10.1121/10.0009383

Received: 19 November 2021 Accepted: 6 January 2022 Published Online: 4 February 2022

1. Introduction

The number of surviving neural elements in the cochlear nerve (CN) and their responsiveness to electrical stimulation (i.e., functional status of the CN) has been shown to be important for cochlear implant (CI) outcomes (Pfingst et al., 2015; Pfingst et al., 2017; Schwartz-Leyzac et al., 2020b; Schwartz-Leyzac and Pfingst, 2018; Skidmore et al., 2020; Zhou and Pfingst, 2014). The sensitivity of the electrically evoked compound action potential (eCAP) to changes in the interphase gap (IPG) (i.e., the IPG effect) is associated with the survival of spiral ganglion neurons (SGNs) in guinea pigs (Prado-Guitierrez et al., 2006; Ramekers et al., 2014; Ramekers et al., 2015; Schwartz-Leyzac et al., 2019), and with the presumed functional status of the CN in human CI users (He et al., 2018; He et al., 2020a; Hughes et al., 2018; Kim et al., 2010; Schwartz-Leyzac and Pfingst, 2016, 2018; Skidmore and He, 2021).

Studies investigating the IPG effect on the eCAP in animal models showed different results from those measured in human CI users. Specifically, guinea pigs with lower densities of SGNs showed (1) larger IPG effects on the eCAP threshold, the maximum eCAP amplitude and the N1 latency, (2) smaller IPG effects on the slope of the eCAP input/output (I/O) function, and (3) smaller stimulation level offsets (Prado-Guitierrez et al., 2006; Ramekers et al., 2014; Ramekers et al., 2015). In contrast, we recently found a different trend in human CI users when comparing the IPG effect between children with cochlear nerve deficiency (CND), i.e., a small or absent CN in imaging results) and children with normalized CNs (NSCNs) (He et al., 2020a; Skidmore and He, 2021). Specifically, compared with children with NSCNs, children with CND tended to have (1) larger IPG effects on the maximum eCAP amplitude and the slope of the eCAP I/O function, (2) smaller IPG effects on the eCAP threshold and the N1 latency, and (3) larger stimulation level offsets (He et al., 2020a; Skidmore and He, 2021).

In addition to differences in species, electrode placement, and duration of deafness (Hughes et al., 2018; He et al., 2020b), the difference in how the IPG effect is quantified across studies might be another important factor accounting for the discrepancy in results reported between animal models and human CI users (Ramekers et al., 2014; He et al., 2020a). Specifically, the IPG effect on the eCAP has been quantified using two methods: the absolute difference method and the proportional difference method. In the absolute difference method, the IPG effect is defined as the difference in eCAP results recorded at different IPGs. This method has been used to quantify the IPG effect on the eCAP I/O function, the maximum eCAP amplitude, and the N1 latency (Ramekers et al., 2014; Schwartz-Leyzac et al., 2020a), as well as the stimulation level offset (Prado-Guitierrez et al., 2006; Kim et al., 2010; Ramekers et al., 2014; Skidmore and He, 2021). In the proportional difference method, the IPG effect on the eCAP is defined as the proportional change relative to the eCAP result measured at one selected IPG. This method has been used to quantify the IPG effect on the slope of eCAP I/O function, the maximum eCAP amplitude, the eCAP threshold, and the N1 latency (Schwartz-Leyzac and Pfingst, 2016; He et al., 2020a).
In addition to the quantification method, the choice of parameter scale (i.e., linear versus logarithmic scale) has been proposed to be important for assessing the IPG effect on the slope of the eCAP I/O function (Brochier et al., 2021). However, this concept has not been verified on other eCAP measurements. This study aimed to demonstrate the importance of the choice of quantification method and parameter scale when reporting the IPG effect.

2. Materials and methods

This study reanalyzed eCAP data collected in He et al. (2020a). The eCAP parameters [i.e., dependent variables (DVs)] evaluated in this study included the eCAP threshold quantified using linear scaling units [i.e., nanocoulombs (nC)], the eCAP threshold quantified using logarithmic scaling units [i.e., clinical current level (CL)], the maximum slope of the eCAP I/O function estimated using the window method (Skidmore et al., 2021) in a logarithmic input scale (μV/dB), the overall slope of the eCAP I/O function estimated using linear regression (Abbas et al., 1999; Kim et al., 2010) in a linear scale (μV/nC), the maximum eCAP amplitude, the N1 latency of the eCAP recorded at the maximum stimulation level, and the stimulation level offset. Outliers when calculating the slope of the I/O function or stimulation level offset were determined based on the goodness of fit (i.e., R²) using the three scaled median absolute deviation criterion (Leys et al., 2013) and removed from further analysis. No outliers were removed for the eCAP threshold, the maximum eCAP amplitude, or the N1 latency.

The IPGs tested in this study included 7 and 42 μs. For the absolute difference method, the IPG effect was quantified using the formula:

\[
\text{Absolute IPG effect size} = \frac{\text{DV measured for 42 μs IPG} - \text{DV measured for 7 μs IPG}}{}
\]

For the proportional difference method, the IPG effect was quantified using the formula:

\[
\text{Proportional IPG effect size} = \frac{\text{Absolute IPG effect size}}{\frac{\text{DV measured for the 7 μs IPG}}{}}
\]

The group differences were compared using two-tailed, paired-samples t-tests. All data and statistical analyses were performed using MATLAB (v2019b, Mathworks Inc., Natick, MA).

3. Results

3.1 IPG effect: Absolute difference

Figure 1 depicts the size of the IPG effect on the seven DVs measured for both subject groups using the absolute difference method. Each panel shows the comparison of the means and standard deviations (SDs) measured for each DV. These results clearly show a group difference for each DV, which was confirmed by results of statistical analysis (Table 1). When increasing the IPG, children with CND had larger changes in the eCAP threshold (Panels A and B) and the stimulation level offset (Panel G), and smaller changes in the slope of the eCAP I/O function (Panels C and D), the maximum eCAP amplitude (Panel E), and the N1 latency (Panel F) than children with NSCNs. Similar trends in group differences were observed when using different parameter scales and slope-fitting methods (Panels A and B, Panels C and D).

3.2 IPG effect: Proportional difference

Figure 2 shows means and SDs of the IPG effect size on the seven DVs measured using the proportional difference method for both subject groups. Compared to children with NSCNs, children with CND showed (1) significantly larger changes in the eCAP threshold calculated on a linear scale (Panel B), the overall slope of the eCAP I/O function calculated with linear regression (Panel D) and the maximum eCAP amplitude (Panel E), and (2) smaller changes in the N1 latency (Panel F) at longer IPGs. There was no statistically significant difference between the two groups for the eCAP threshold.
calculated on a logarithmic scale (Panel A), the maximum slope of the eCAP function calculated with the window method (Panel C), or the stimulation level offset (Panel G). The results of statistical analyses for each DV are provided in Table 1.

4. Discussion

The primary goal of this study was to investigate how different analysis methods affect the interpretation of the IPG effect. The present study showed that the group difference in IPG effect size on the eCAP could be greatly influenced by the quantification method and scale selection.

4.1 Quantification method

The difference in magnitude and direction of the group difference in IPG effect size was highly dependent on the eCAP parameter and quantification method. Specifically, the group difference changed direction for the linear slope and the maximum eCAP amplitude when changing from the absolute difference (similar trend as Schwartz-Leyzac et al., 2020a) to the proportional difference (same trend as He et al., 2020a). The group difference went from being significant to non-significant for the eCAP threshold calculated in a logarithmic scale, the slope calculated using the window method, and the stimulation level offset. Finally, the group difference was the same direction and remained statistically significant for the N1 latency and the eCAP threshold calculated in a linear scale.

4.2 Scale selection

Results of this study also showed that both the magnitude and the direction of group difference in IPG effect size could be dependent on the scale in which the eCAP threshold was calculated. Specifically, the relative group difference in IPG effect size was much larger when the eCAP threshold was calculated on a linear scale than on a logarithmic scale when using the absolute difference method [Figs. 1(A) and 1(B), respectively]. When using the proportional difference method, children with CND showed relatively smaller IPG effects on the eCAP threshold calculated on a logarithmic scale [Fig. 2(A)], but larger IPG effects on the eCAP threshold calculated on a linear scale [Fig. 2(B)].

The effect of method and scale on estimating the slope of the eCAP I/O function has been detailed in Skidmore et al. (2021), and therefore, is not discussed in this brief report.

4.3 Study limitations

It should be pointed out that some non-neural factors (e.g., electrode placement, impedance, etc.) can affect the IPG effect calculated using the absolute difference method on the slope of eCAP I/O function, the maximum eCAP amplitude, and

| Dependent variable | Absolute difference | Proportional difference |
|--------------------|----------------------|-------------------------|
| eCAP threshold (CL) | $t_{(89)} = -4.96, p < 0.001$ | $t_{(89)} = 1.69, p = 0.094$ |
| eCAP threshold (nC) | $t_{(89)} = -3.33, p < 0.001$ | $t_{(89)} = -4.83, p < 0.001$ |
| Window slope ($\mu V/\text{dB}$) | $t_{(63)} = -2.49, p = 0.015$ | $t_{(63)} = -0.34, p = 0.731$ |
| Linear slope ($\mu V/\text{nC}$) | $t_{(60)} = -5.05, p < 0.001$ | $t_{(60)} = 2.76, p = 0.008$ |
| Maximum eCAP ($\mu V$) | $t_{(89)} = -3.94, p < 0.001$ | $t_{(89)} = 3.11, p = 0.003$ |
| N1 latency ($\mu s$) | $t_{(89)} = -3.09, p = 0.003$ | $t_{(89)} = -4.43, p < 0.001$ |
| Stimulation level offset (CL) | $t_{(68)} = 6.70, p < 0.001$ | $t_{(68)} = -0.50, p = 0.620$ |

Fig. 2. The means and SDs of the interphase gap (IPG) effect size on the seven dependent variables calculated with the proportional difference method. Results measured in children with cochlear nerve deficiency (CND) and children with normal-sized cochlear nerves (NSCNs) are indicated using filled bars and open bars, respectively.
the N1 latency. These non-neural factors should not affect the IPG effect calculated using the proportional difference method on these eCAP parameters. Unfortunately, we do not have sufficient data to fully assess the impact of these non-neural factors on the difference in IPG effects quantified used these two methods, which is a potential limitation of this study.

Due to the retrospective nature of this study and the inherent limitation of working with clinical patient populations, we are unable to unravel the neurophysiological mechanisms underlying the complicated data pattern reported in this study, which is another potential limitation. Further studies are definitely warranted.

5. Conclusion

Results of this study revealed that the method for quantifying the IPG effect size and the choice of parameter scale impact the results and their interpretations of the IPG effect on the eCAP between children with CND and children with NSCNs. Robust group differences in the IPG effect on several eCAP parameters are still observed when different analyzing techniques are applied, which further supports the idea that eCAP sensitivity to changes in IPG can provide an indicator for the functional status of the CN in human CI users. However, a careful selection of eCAP parameters and specifying how the IPG effect is quantified are critical for accurate result calculation and interpretation for any studies that include the IPG effect as part of the testing paradigms.

Acknowledgments

This work was supported by the R01 Grant No. R01 DC 017846 from NIDCD, the R01 Grant No. R01 DC 016038 from NIDCD and NIGMS, and the R21 Grant No. R21DC019458 from NIDCD.

References and links

Abbas, P. J., Brown, C. J., Shallop, J. K., Firszt, J. B., Hughes, M. L., Hong, S. H., and Staller, S. J. (1999). "Summary of results using the nucleus ci42m implant to record the electrically evoked compound action potential," *Ear Hear.* **20**(1), 45–59.

Brochier, T., McKay, C. M., and Carlyon, R. P. (2021). "Interpreting the effect of stimulus parameters on the electrically evoked compound action potential and on neural health estimates," *JARO - Journal of the Association for Research in Otolaryngology* **22**, 81–94.

He, S., Shahravarni, B. S., McFayden, T. C., Wang, H., Gill, K. E., Xu, L., Chao, X., Luo, J., Wang, R., and He, N. (2018). "Responsiveness of the electrically stimulated cochlear nerve in children with cochlear nerve deficiency," *Ear Hear.* **39**(2), 238–250.

He, S., Xu, L., Skidmore, J., Chao, X., Jeng, F.-C., Wang, R., Luo, J., and Wang, H. (2020a). "The effect of interphase gap on neural response of the electrically stimulated cochlear nerve in children with cochlear nerve deficiency and children with normal-sized cochlear nerves," *Ear Hear.* **41**(4), 918–934.

He, S., Xu, L., Skidmore, J., Chao, X., Riggs, W. J., Wang, R., Vaughan, C., Luo, J., Shannon, M., and Warner, C. (2020b). "Effect of increasing pulse phase duration on neural responsiveness of the electrically stimulated cochlear nerve," *Ear Hear.* **41**(6), 1606–1618.

Hughes, M. L., Choi, S., and Glickman, E. (2018). "What can stimulus polarity and interphase gap tell us about auditory nerve function in cochlear-implant recipients?" *Hear. Res.* **359** (March 2018), 50–63.

Kim, J.-R., Abbas, P. J., Brown, C. J., Etler, C. P., O’Brien, S., and Kim, L.-S. (2010). "The relationship between electrically evoked compound action potential and speech perception: A study in cochlear implant users with short electrode array," *Otol. Neurotol.* **31**(7), 1041–1048.

Leys, C., Ley, C., Klein, O., Bernard, P., and Licata, L. (2013). "Detecting outliers: Do not use standard deviation around the mean, use absolute deviation around the median," *J. Exp. Soc. Psychol.* **49**(4), 764–766.

Pfingst, B. E., Colesa, D. J., Sviderski, D. L., Hughes, A. P., Strahl, S. B., Sinan, M., and Raphael, Y. (2017). "Neurotrophin gene therapy in deafened ears with cochlear implants: long-term effects on nerve survival and functional measures," *J. Assoc. Res. Otolaryngol.* **18**(6), 731–750.

Pfingst, B. E., Zhou, N., Colea, D. J., Watts, M. M., Strahl, S. B., Garadat, S. N., Schwartz-Leyzac, K. C., Budenz, C. L., Raphael, Y., and Zwolan, T. A. (2015). "Importance of cochlear health for implant function," *Hear. Res.* **322**(April 2015), 77–88.

Prado-Gutierrez, P., Fewster, L. M., Heasman, J. M., McKay, C. M., and Shepherd, R. K. (2006). "Effect of interphase gap and pulse duration on electrically evoked potentials is correlated with auditory nerve survival," *Hear. Res.* **215**(1–2), 47–55.

Ramekers, D., Versnel, H., Strahl, S. B., Kls, S. F. L., and Grolman, W. (2015). "Temporary neurotrophin treatment prevents deafness-induced auditory nerve degeneration and preserves function," *J. Neurosci.* **35**(36), 12331–12345.

Ramekers, D., Versnel, H., Strahl, S. B., Smeets, E. M., Kls, S. F. L., and Grolman, W. (2014). "Auditory-nerve responses to varied interphase gap and phase duration of the electric pulse stimulus as predictors for neuronal degeneration," *J. Assoc. Res. Otolaryngol.* **15**(2), 187–202.

Schwartz-Leyzac, K. C., Colea, D. J., Buswinka, C. J., Rabah, A. M., Sviderski, D. L., Raphael, Y., and Pfingst, B. E. (2020a). "How electrically evoked compound action potentials in chronically implanted guinea pigs relate to auditory nerve health and electrode impedance," *J. Acoust. Soc. Am.* **148**(6), 3900–3912.

Schwartz-Leyzac, K. C., Colea, D. J., Buswinka, C. J., Sviderski, D. L., Raphael, Y., and Pfingst, B. E. (2019). "Changes over time in the electrically evoked compound action potential (ECAP) interphase gap (IPG) effect following cochlear implantation in Guinea pigs," *Hear. Res.* **383**, 107809.

Schwartz-Leyzac, K. C., Holden, T. A., Zwolan, T. A., Arts, H. A., Firszt, J. B., Buswinka, C. J., and Pfingst, B. E. (2020b). "Effects of electrode location on estimates of neural health with cochlear implants," *J. Assoc. Res. Otolaryngol.* **21**, 259–275.

Schwartz-Leyzac, K. C., and Pfingst, B. E. (2016). "Across-site patterns of electrically evoked compound action potential amplitude-growth functions in multichannel cochlear implant recipients and the effects of the interphase gap," *Hear. Res.* **341**, 50–65.
Schvartz-Leyzac, K. C., and Pfingst, B. E. (2018). “Assessing the relationship between the electrically evoked compound action potential and speech recognition abilities in bilateral cochlear implant recipients,” Ear Hear. 39(2), 344–358.

Skidmore, J., and He, S. (2021). “The effect of increasing interphase gap on N1 latency of the electrically evoked compound action potential and the stimulation level offset in human cochlear implant users,” Ear Hear. 42(1), 244–247.

Skidmore, J., Ramekers, D., Colesa, D. J., Schvartz-Leyzac, K. C., Pfingst, B. E., and He, S. (2021). “A broadly applicable method for characterizing the slope of the electrically evoked compound action potential amplitude growth function,” Ear and Hearing. Published online. Retrieved from https://journals.lww.com/ear-hearing/Fulltext/9000/A_Broadly_Applicable_Method_for_Characterizing_the.98484.aspx.

Skidmore, J., Xu, L., Chao, X., Riggs, W. J., Pellittieri, A., Vaughan, C., Ning, X., Wang, R., Luo, J., and He, S. (2020). “Prediction of the functional status of the cochlear nerve in individual cochlear implant users using machine learning and electrophysiological measures,” Ear Hear. 42(1), 180–192.

Zhou, N., and Pfingst, B. E. (2014). “Relationship between multipulse integration and speech recognition with cochlear implants,” J. Acoust. Soc. Am. 136(3), 1257–1268.